Bar Harbor Wealth Management Has $2.62 Million Holdings in Thermo Fisher Scientific Inc. $TMO

Bar Harbor Wealth Management lessened its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.4% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,471 shares of the medical research company’s stock after selling 300 shares during the period. Bar Harbor Wealth Management’s holdings in Thermo Fisher Scientific were worth $2,624,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. CBIZ Investment Advisory Services LLC lifted its stake in Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock worth $28,000 after purchasing an additional 33 shares during the last quarter. Anderson Financial Strategies LLC bought a new stake in Thermo Fisher Scientific during the first quarter worth $30,000. Keystone Global Partners LLC bought a new stake in Thermo Fisher Scientific during the first quarter worth $31,000. DiNuzzo Private Wealth Inc. lifted its stake in Thermo Fisher Scientific by 406.7% during the second quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock worth $31,000 after purchasing an additional 61 shares during the last quarter. Finally, HighMark Wealth Management LLC lifted its stake in Thermo Fisher Scientific by 140.6% during the second quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company’s stock worth $31,000 after purchasing an additional 45 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on TMO. Redburn Partners set a $580.00 target price on Thermo Fisher Scientific in a research note on Wednesday. Evercore ISI upped their price target on shares of Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an “outperform” rating in a report on Tuesday. Scotiabank upgraded shares of Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 price target for the company in a report on Friday, July 11th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Thermo Fisher Scientific in a report on Saturday, September 27th. Finally, Raymond James Financial reiterated an “outperform” rating and set a $535.00 price target (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Fifteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $590.60.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $536.21 on Thursday. The company has a market capitalization of $202.48 billion, a price-to-earnings ratio of 31.01, a PEG ratio of 2.93 and a beta of 0.77. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97. The stock has a fifty day simple moving average of $486.09 and a 200 day simple moving average of $448.21. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same period in the prior year, the business posted $5.37 earnings per share. Thermo Fisher Scientific’s quarterly revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the sale, the chief accounting officer owned 2,319 shares of the company’s stock, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 30,066 shares of company stock worth $14,182,963. Company insiders own 0.33% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.